Royal North Shore Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (7)

2023

  1. Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY

    eClinicalMedicine, Vol. 65

2020

  1. A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: The ASPEN study

    Blood, Vol. 136, Núm. 18, pp. 2038-2050

  2. Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: A substudy of the phase 3 ASPEN trial

    Blood Advances, Vol. 4, Núm. 23, pp. 6009-6018

2014

  1. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia

    British Journal of Haematology, Vol. 167, Núm. 4, pp. 466-477

  2. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: Pivotal study update demonstrates durable responses

    Journal of Hematology and Oncology, Vol. 7, Núm. 1

  3. Tolerability to romidepsin in patients with relapsed/refractory T-cell lymphoma

    Biomarker Research, Vol. 2, Núm. 1

2012

  1. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy

    Journal of Clinical Oncology, Vol. 30, Núm. 6, pp. 631-636